|Abuse of amphetamines and structural abnormalities in the brain.|
|PMID: 18991959 Owner: NLM Status: MEDLINE|
|We review evidence that structural brain abnormalities are associated with abuse of amphetamines. A brief history of amphetamine use/abuse and evidence for toxicity is followed by a summary of findings from structural magnetic resonance imaging (MRI) studies of human subjects who had abused amphetamines and children who were exposed to amphetamines in utero. Evidence comes from studies that used a variety of techniques including manual tracing, pattern matching, voxel-based, tensor-based, or cortical thickness mapping, quantification of white matter signal hyperintensities, and diffusion tensor imaging. Ten studies compared controls to individuals who were exposed to methamphetamine. Three studies assessed individuals exposed to 3-4-methylenedioxymethamphetamine (MDMA). Brain structural abnormalities were consistently reported in amphetamine abusers, as compared to control subjects. These included lower cortical gray matter volume and higher striatal volume than control subjects. These differences might reflect brain features that could predispose to substance dependence. High striatal volumes might also reflect compensation for toxicity in the dopamine-rich basal ganglia. Prenatal exposure was associated with striatal volume that was below control values, suggesting that such compensation might not occur in utero. Several forms of white matter abnormality are also common and may involve gliosis. Many of the limitations and inconsistencies in the literature relate to techniques and cross-sectional designs, which cannot infer causality. Potential confounding influences include effects of pre existing risk/protective factors, development, gender, severity of amphetamine abuse, abuse of other drugs, abstinence, and differences in lifestyle. Longitudinal designs in which multimodal datasets are acquired and are subjected to multivariate analyses would enhance our ability to provide general conclusions regarding the associations between amphetamine abuse and brain structure.|
|Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London|
Related Documents :
|2229579 - Cranial mr imaging in hypomelanosis of ito.
1881549 - Ct and mr imaging of cns lymphomatoid granulomatosis.
16565589 - Surgical removal of a live worm by stereotactic targeting in cerebral sparganosis. case...
3817319 - High density on computed tomography in infantile krabbe's disease: a case report.
24338999 - Comparison of optimized long echo time steam and press proton mr spectroscopy of lipid ...
15548489 - Temporal evolution of water diffusion parameters is different in grey and white matter ...
10512909 - Lack of evidence of acute ischemic tissue change in transient global amnesia on single-...
20055389 - Slow magnetic relaxation in a high-spin iron(ii) complex.
23724609 - The hypertrophy of the lateral abdominal wall and quadratus lumborum is sport-specific:...
|Type: Journal Article; Research Support, N.I.H., Extramural; Review|
|Title: Annals of the New York Academy of Sciences Volume: 1141 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2008 Oct|
|Created Date: 2008-11-10 Completed Date: 2008-12-12 Revised Date: 2014-09-21|
Medline Journal Info:
|Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States|
|Languages: eng Pagination: 195-220 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Amphetamine-Related Disorders / pathology*
Amphetamines / adverse effects*, therapeutic use, toxicity
Attention Deficit Disorder with Hyperactivity / drug therapy, pathology
Brain / abnormalities, drug effects, pathology*
Magnetic Resonance Imaging
Methamphetamine / toxicity
Myelin Sheath / drug effects, pathology
N-Methyl-3,4-methylenedioxyamphetamine / toxicity
Neurons / drug effects
Neurotransmitter Agents / metabolism
Prenatal Exposure Delayed Effects
|M01 RR000865/RR/NCRR NIH HHS; M01 RR000865-270065/RR/NCRR NIH HHS; M01 RR00865/RR/NCRR NIH HHS; P20 DA022539/DA/NIDA NIH HHS; P20 DA022539/DA/NIDA NIH HHS; P20 DA022539-01/DA/NIDA NIH HHS; P20 DA022539-02/DA/NIDA NIH HHS; P20 DA022539-03/DA/NIDA NIH HHS; R01 DA015179/DA/NIDA NIH HHS; R01 DA015179/DA/NIDA NIH HHS; R01 DA015179-01A1/DA/NIDA NIH HHS; R01 DA015179-02/DA/NIDA NIH HHS; R01 DA015179-03/DA/NIDA NIH HHS; R01 DA020726/DA/NIDA NIH HHS; R01 DA020726/DA/NIDA NIH HHS; R01 DA020726-01/DA/NIDA NIH HHS; R01 DA020726-02/DA/NIDA NIH HHS; R01 DA020726-03/DA/NIDA NIH HHS; R01 DA020726-04/DA/NIDA NIH HHS; R03 DA020512/DA/NIDA NIH HHS; R03 DA020512-01/DA/NIDA NIH HHS; R03 DA20512/DA/NIDA NIH HHS; R21 DA023192/DA/NIDA NIH HHS; R21 DA023192/DA/NIDA NIH HHS; R21 DA023192-01/DA/NIDA NIH HHS; R21 DA023192-02/DA/NIDA NIH HHS|
|0/Amphetamines; 0/Neurotransmitter Agents; 44RAL3456C/Methamphetamine; KE1SEN21RM/N-Methyl-3,4-methylenedioxyamphetamine|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.
Next Document: Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and thera...